Frontlight ResearchEarly access
Not yet taking people in FrancePhase 4
Compares anti-TNF, vedolizumab and tofacitinib for ulcerative colitis and blood vessel health
Compares anti-TNF, vedolizumab and tofacitinib on blood vessels in adults with ulcerative colitis.
Key facts
- Who runs it
- Centre Hospitalier Universitaire Amiens Picardie
- Where
- Amiens Cedex 1, FranceSee the site
- Registry title
- IMPACT OF ANTI-TNF, VEDOLIZUMAB AND TOFACITINIB ON AORTIC STIFFNESS, CAROTID INTIMA-MEDIA THICKNESS AND CARDIOVASCULAR RISK OF PATIENTS WITH ULCERATIVE COLITIS
- Status
- Not yet recruiting
- Phase
- Phase 4
- People taking part
- 100 people, planned
- Started
- 3 Jun 2021
- Planned end
- 2 Jun 2026
- Type of study
- Interventional
- Record updated
- 10 September 2024
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with ulcerative colitis who are about to start infliximab, adalimumab, golimumab, vedolizumab or tofacitinib. It looks at how these drugs affect artery thickness.
- Age
- Older than 18 years
- Sex
- Men and women
- Disease stage
- Ulcerative colitis present for at least 6 months
- Earlier treatment
- Must be starting treatment with infliximab, adalimumab, golimumab, vedolizumab or tofacitinib. Blood pressure, antiplatelet or cholesterol drugs must have a stable dose in the 3 months before and during the study.
Main reasons for not taking part
- Heart attack or stroke
- Diabetes
- Pregnant or breastfeeding women
- Not covered by French national health insurance
- Under 18 years old, or deprived of liberty or under guardianship
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- Ulcerative colitis evolving for at least 6 months
- Patient older than 18 years
- Initiating a treatment by infliximab, adalimumab, golimumab, vedolizumab or tofacitinib
- Patient covered by French national health insurance
- Written informed consent
Who cannot take part
- Patients with anti-hypertensive, antiplatelet or lipid-lowering drugs without stable dosage within the 3 months before the study and over the study period
- Patients with a cardiovascular event such as myocardial infarction and stroke
- Diabetic patient
- Pregnant women or breastfeeding
- Minor
- Patient deprived of liberty by administrative or judicial decision or placed under judicial protection (guardianship or supervision)
Where in France
- Centre Hospitalier Universitaire Amiens PicardieAmiens Cedex 1, FranceNot yet recruiting
About the trial
What the trial wants to find out
To compare the CIMT after 3 months of therapy in ulcerative colitis in patients treated by anti-TNF, vedolizumab, and tofacitinib
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).
- Official title
- IMPACT OF ANTI-TNF, VEDOLIZUMAB AND TOFACITINIB ON AORTIC STIFFNESS, CAROTID INTIMA-MEDIA THICKNESS AND CARDIOVASCULAR RISK OF PATIENTS WITH ULCERATIVE COLITIS
- Plain-language title
- Compares anti-TNF, vedolizumab and tofacitinib for ulcerative colitis and blood vessel healthGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 10 September 2024